TY - JOUR
T1 - Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery
AU - Ding, Qian
AU - Zhang, Zugui
AU - Liu, Hong
AU - Nie, Huang
AU - Berguson, Mark
AU - Goldhammer, Jordan E.
AU - Young, Nilas
AU - Boyd, Walter D
AU - Morris, Rohinton
AU - Sun, Jianzhong
PY - 2019/9/13
Y1 - 2019/9/13
N2 - It remains disputable about perioperative use of renin-angiotensin system inhibitors (RASi) and their outcome effects. This multicenter retrospective cohort study examines association between use of perioperative RASi and outcomes in patients undergoing coronary artery bypass graft and/or valve surgery. After the exclusion, the patients are divided into 2 groups with or without preoperative RASi (PreRASi, n = 8581), or 2 groups with or without postoperative RASi (PostRASi, n = 8130). With using of propensity scores matching to reduce treatment selection bias, the study shows that PreRASi is associated with a significant reduction in postoperative 30-day mortality compared with without one (3.41% vs. 5.02%); PostRASi is associated with reduced long-term mortality rate compared with without one (6.62% vs. 7.70% at 2-year; 17.09% vs. 19.95% at 6-year). The results suggest that perioperative use of RASi has a significant benefit for the postoperative and long-term survival among patients undergoing cardiac surgery.
AB - It remains disputable about perioperative use of renin-angiotensin system inhibitors (RASi) and their outcome effects. This multicenter retrospective cohort study examines association between use of perioperative RASi and outcomes in patients undergoing coronary artery bypass graft and/or valve surgery. After the exclusion, the patients are divided into 2 groups with or without preoperative RASi (PreRASi, n = 8581), or 2 groups with or without postoperative RASi (PostRASi, n = 8130). With using of propensity scores matching to reduce treatment selection bias, the study shows that PreRASi is associated with a significant reduction in postoperative 30-day mortality compared with without one (3.41% vs. 5.02%); PostRASi is associated with reduced long-term mortality rate compared with without one (6.62% vs. 7.70% at 2-year; 17.09% vs. 19.95% at 6-year). The results suggest that perioperative use of RASi has a significant benefit for the postoperative and long-term survival among patients undergoing cardiac surgery.
UR - http://www.scopus.com/inward/record.url?scp=85072200441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072200441&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-11678-9
DO - 10.1038/s41467-019-11678-9
M3 - Article
C2 - 31519895
AN - SCOPUS:85072200441
VL - 10
JO - Nature Communications
JF - Nature Communications
SN - 2041-1723
IS - 1
ER -